Genmab — September 2019
-
-
Tusinde tak Bulder igen i igen.
-
Tror også at markedet afventer pressemødet.
-
Netop...Pressemødet tager som regel gassen ud af ballonen.
-
Jeg har ikke mange andre aktier end Genmab som ikke er rød lige nu.
-
Det ender nok TA-mæssigt med en "Vomiting Camel" : https://www.ft.com/video/2452d265-ef0e-4f7f-b0b2-ca1dc076ff33
-
Enjoy..Jeg har den med i mine foredrag.
-
Completion of the Phase 3 CANDOR study evaluating KYPROLIS in combination with dexamethasone and DARZALEX
(daratumumab) (KdD) compared to KYPROLIS and dexamethasone alone in patients with relapsed or refractory multiple myeloma is expected in the second half of 2019. https://www.prnewswire.com/news-releases/amgen-highlights-new-data-from-kyprolis-carfilzomib-and-oncology-pipeline-at-imw-2019-300916681.html -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind